Aldevron

ICYMI Decisions made in the discovery stage for therapeutics can be critical when the time for manufacturing comes. Taking manufacturing processes into consideration when making those decisions can be a key to success, as Emilija Robinson discusses in her blog post, Had I Known Then What I Know Now. https://lnkd.in/gsgbwUEZ #inthenews

Tomorrow is the day for our Fierce Biotech Webinar where we will introduce our innovative solutions that include Codex® HiCap T7 RNA Polymerase. The production of mRNA using HiCap minimizes dsRNA formation during IVT, which may eliminate the need for a secondary chromatography step in downstream purification. This paves the way for the development of safer and more potent mRNA-based medicines with simpler and more economical manufacturing workflows. Secure your spot today! https://lnkd.in/gFK3J23i

Don't miss this Fierce Biotech Webinar where we will introduce our innovative solutions that include Codex® HiCap T7 RNA Polymerase. The production of mRNA using HiCap minimizes dsRNA formation during IVT, which may eliminate the need for a secondary chromatography step in downstream purification. This paves the way for the development of safer and more potent mRNA-based medicines with simpler and more economical manufacturing workflows. Secure your spot today! https://lnkd.in/g6v7DnbK

Decisions made in the discovery stage for therapeutics can be critical when the time for manufacturing comes. Taking manufacturing processes into consideration when making those decisions can be a key to success, as Emilija Robinson discusses in her blog post, Had I Known Then What I Know Now. https://lnkd.in/gxUVk9-K #inthenews

ICYMI From new approaches to therapeutic development to dealing with the biggest challenges in gene editing, Alex Liu came away inspired from the International Society for Cell & Gene Therapy annual meeting. He shares some of what he sees as the potential of cell and gene editing in the near future in his blog post, Breaking Boundaries for Future Treatments. https://lnkd.in/gKpn62NK @inthenews

The power of collaboration was evident today as we welcomed Dr. Fyodor Urnov from the Innovative Genomics Institute to Aldevron’s Madison, WI, site. #TeamAldevron staffed facility tour stops as Dr. Urnov and colleagues from Danaher Corporation and Integrated DNA Technologies, learned more about our work and our facility. The highlight was Dr. Urnov’s “Lunch and Learn” presentation “The Danaher-IGI Beacon for CRISPR Cures: From N=rare to N=all," to our on-site associates, and those tuning in around the globe. His enthusiasm for our work and the potential for the Danaher-IGI Beacon for CRISPR Cures, launched earlier this year, was unmistakable.   “We have the right leadership with the right vision. I solute IDT and Aldevron for their corporate culture that is committed to innovate.” #CRISPR Tom Foti Anu Codaty Rolf Turk Sandy Ottensmann Jennifer Moody Sadik Kassim #inthenews

Happy World RNA Day from the Aldevron team! August 1 was named #RNADay in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Although not as well-known as DNA, we recognize the exciting potential of #RNA in #drugdevelopment every day at Aldevron. In our latest case study, “Comprehensive pathway to seamless scale-up of mRNA drug product manufacturing,” we detail how we've streamlined production from sequence to final product, ensuring top-notch quality, regulatory compliance, and seamless coordination. Read that case study here: https://lnkd.in/gNYCQ8Vn And we welcome you to learn more about how we help organizations take #RNA from concept to clinical trial (and beyond), by also downloading our service brochure: https://lnkd.in/gcyhb6JZ #inthenews

As the field of mRNA-based medicines advances, both developers and regulatory agencies are prioritizing safety. The presence of double-stranded RNA (dsRNA) impurities, a byproduct of mRNA synthesis by in vitro transcription (IVT), can compromise the safety as well as the potency of mRNA vaccines and therapeutics. Don't miss this Fierce Biotech Webinar where we will introduce our innovative solutions that include Codex® HiCap T7 RNA Polymerase. The production of mRNA using HiCap minimizes dsRNA formation during IVT, which may eliminate the need for a secondary chromatography step in downstream purification. This paves the way for the development of safer and more potent mRNA-based medicines with simpler and more economical manufacturing workflows. Secure your spot today! https://lnkd.in/gr72kqeM

Overcoming manufacturing challenges will be essential for large-scale use of mRNA therapies. A recent paper demonstrates how Codex® HiCap RNA Polymerase enables efficient co-transcriptional capping with reduced dsRNA byproducts. This enzyme is now available exclusively through Aldevron, contact us to see how it can enhance IVT in your program. https://lnkd.in/efWJ6cxZ

ICYMI One of the issues in #RNA therapeutic development is the cost of the process, along with lengthy timelines. However, would the application of Moore’s Law for computing provide a roadmap to overcoming those obstacles? As Kyle Studey discusses in his post, Rise of the Machine, artificial intelligence (#AI) could be the next big step for drug developers. https://lnkd.in/gABnx8tM